J&J Stresses New China Disease Strategy
This article was originally published in PharmAsia News
Growing by double digits, the world’s largest healthcare company is leveraging its diversified platform and working with the government to tackle highly prevalent local diseases, including lung cancer in the case of China.
You may also be interested in...
As the largest manufacturer of active pharmaceutical ingredients globally, China is bracing for more uncertainty amid the global pandemic and fast-changing environment, particularly in the US.
Despite leading multinational pharma firms including AstraZeneca again delivering double-digit growth in China, the impact of coronavirus and an expanding volume-based purchasing scheme begin to surface.
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.